Month: November 2022

IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that Ronnie Andrews will step down from his role as Chief Executive Officer and as a director of the Company’s board of directors effective December 1, 2022. In order to ensure a smooth transition effective as of December 2, 2022, Joshua Riggs will serve as interim Chief Executive Officer until such time as a new CEO has been identified and retained and Mr. Andrews will continue to act a consultant until February 28, 2023. Mr. Riggs, who has been Oncocyte’s General Manager, Transplant since July 2022 and was the Company’s Senior Director Business Development...

Data from first two dose levels of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma support continued dose escalation to determine the optimal recommended Phase 2 dose SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today reported preliminary dose-ranging data from the first two dose levels of the dose escalation part of the Phase 1b/2 study of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). The data are featured in an abstract accepted for a poster presentation at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO), which is taking place both virtually and in-person at the...

– Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy – – Updated interim Phase I/II results show encouraging safety and tolerability profile with potential for deep and durable responses in NSCLC with cNeT and reduced-dose lymphodepletion and IL-2 – – Company to host a conference call and webcast on December 6, 2022 at 8:00am ET / 1:00pm UK – LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that an abstract highlighting updated interim results from the ongoing Phase I/IIa CHIRON and THETIS clinical trials evaluating clonal neoantigen-reactive...

IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced the appointment of Louis E. Silverman as an independent member of its board of directors, effective immediately. “I am pleased to announce the appointment of Lou as a member of our Board,” said Andy Arno, Chair of Oncocyte’s Board of Directors. “Lou’s 25+-year track record of success as CEO in health care IT and health care services companies will assuredly be accretive to the Company’s strategic goals. We are confident that Lou’s expertise in health care innovation and execution, together with his experienced leadership skills will be of tremendous and...

CORRECTION: Increase of share capital of Play and results of share offering A shareholders‘ meeting of Fly Play hf. held on 30 November 2022 approved the below stated proposals, which authorise the board of directors decided to increase the Company‘s share capital by up to ISK 228.670.505 in nominal value with the issuance of new shares. The goal of the share capital increase is to strengthen the company for the coming growth and to ensure its strong liquidity position. Play‘s 20 largest shareholders participated in the increase. To ensure shareholder equality all shareholders were afforded the opportunity to subscribe for new shares on the same terms. As the current market value of shares is lower than the subscription price there was very limited participation. As a result of the above the following matters were on the agenda of the...

TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) — REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) is pleased to announce that it is arranging a private placement of a minimum of $3 million and up to $5 million of units (each, a “Unit”), at a price of $0.15 per Unit; (the “Offering”). The Offering is being led by EMD Financial Inc. Each Unit shall be comprised of one common share (“Common Share”) in the capital of the Company and one (1) Common Share purchase warrant (“Warrant”) of the Company. Each Warrant shall entitle the holder thereof to acquire one additional Common Share at a price of $0.20 for a period of thirty-six (36) months from the closing date (the “Closing Date”) of the Offering. There is an offering document (the “Offering Document”) related to the Offering that can be accessed under the Company’s...

CALGARY, Alberta, Nov. 30, 2022 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (“DIRTT” or the “Company”) (TSX:DRT, NASDAQ:DRTT), a global leader in industrialized construction, is pleased to announce the successful closing of its previously announced private placement of common shares of the Company (“Common Shares”) to insiders of the Company for aggregate gross proceeds of approximately US$2.8 million (the “Private Placement”). Pursuant to the Private Placement, the Company issued an aggregate of 8,667,449 Common Shares to 22 NW Fund, LP (“22NW”), 726 BC LLC and 726 BF LLC (together “726”), and all of the directors and executive officers of the Company at a subscription price of US$0.32 per Common Share (the “Subscription Price”), including 638,996 Common Shares...

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) — Hampton Financial Corporation (“Hampton” or the “Corporation”) (TSXV: HFC) (TSXV: HFC.PR.A) is pleased to announce the closing of the second and final tranche of a non-brokered private placement of unsecured convertible debentures (the “Debentures”) in the principal amount of $385,000. The closing of the second and final tranche is part of a larger additional offering of Debentures in the aggregate principal amount of up to CAD$5,500,000 (the “Offering”). Pursuant to the Offering Hampton completed two tranches of Debentures in the aggregate principal amount of $3,021,000, completion of the first tranche having been announced on November 7, 2022. Hampton had also announced on October 11, 2022 completion...